{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:37:33Z","timestamp":1782391053768,"version":"3.54.5"},"reference-count":59,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100014305","name":"HIV Research Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014305","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In this study the influence of first\u2010line antimalarial drug artemether\u2010lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV\u2010infected Nigerian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a two\u2010period, single sequence crossover study. In stage 1, 150 HIV\u2010infected patients receiving nevirapine\u2010based antiretroviral regimens were enrolled and genotyped for seven SNPs. Sparse pharmacokinetic sampling was conducted to identify SNPs independently associated with nevirapine plasma concentration. Patients were categorized as poor, intermediate and extensive metabolizers based on the numbers of alleles of significantly associated SNPs. Intensive sampling was conducted in selected patients from each group. In stage 2, patients received standard artemether\u2010lumefantrine treatment with nevirapine, and intensive pharmacokinetic sampling was conducted on day 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No clinically significant changes were observed in key nevirapine pharmacokinetic parameters, the 90% confidence interval for the measured changes falling completely within the 0.80\u20131.25 no\u2010effect boundaries. However, the number of patients with trough plasma nevirapine concentration below the 3400\u00a0ng\u00a0ml\n                      <jats:sup>\u22121<\/jats:sup>\n                      minimum effective concentration increased from 10% without artemether\u2010lumefantrine (all extensive metabolizers) to 21% with artemether\u2010lumefantrine (14% extensive, 4% intermediate, and 3% poor metabolizers).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolizers when nevirapine is co\u2010administered with artemether\u2010lumefantrine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.13821","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T11:49:52Z","timestamp":1543060192000},"page":"540-550","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacogenetics of artemether\u2010lumefantrine influence on nevirapine disposition: Clinically significant drug\u2013drug interaction?"],"prefix":"10.1111","volume":"85","author":[{"given":"Sa'ad T.","family":"Abdullahi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry Obafemi Awolowo University Ile\u2010Ife Nigeria"},{"name":"Department of Pharmaceutical and Medicinal Chemistry University of Ilorin Ilorin Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6588-5749","authenticated-orcid":false,"given":"Adeniyi","family":"Olagunju","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry Obafemi Awolowo University Ile\u2010Ife Nigeria"},{"name":"Department of Molecular and Clinical Pharmacology University of Liverpool 70 Pembroke Place Liverpool L69 3GF UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius O.","family":"Soyinka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry Obafemi Awolowo University Ile\u2010Ife Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahman A.","family":"Bolarinwa","sequence":"additional","affiliation":[{"name":"Department of Haematology Obafemi Awolowo University Teaching Hospitals Complex Ile\u2010Ife Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusola J.","family":"Olarewaju","sequence":"additional","affiliation":[{"name":"Department of Haematology Obafemi Awolowo University Teaching Hospitals Complex Ile\u2010Ife Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moji T.","family":"Bakare\u2010Odunola","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Medicinal Chemistry University of Ilorin Ilorin Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology University of Liverpool 70 Pembroke Place Liverpool L69 3GF UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology University of Liverpool 70 Pembroke Place Liverpool L69 3GF UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"WHO.World Health Organization's World Malaria Report2015. Geneva Switzerland [Online]. Available athttp:\/\/www.who.int\/malaria\/publications\/world\u2010malaria\u2010report\u20102015\/report\/en\/(last accessed 12 October 2016)."},{"key":"e_1_2_8_3_1","unstructured":"UNAIDS.UN Joint Programme on HIV\/AIDS Global AIDS Update \u2013 2016 June2016[Online]. Available athttp:\/\/www.refworld.org\/docid\/574e8d394.html(last accessed 3 April 2017)."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/27.2.296"},{"key":"e_1_2_8_5_1","unstructured":"UNAIDS.UN Joint Programme on HIV\/AIDS Prevention Gap Report January2016[Online]. Available athttp:\/\/www.refworld.org\/docid\/57862e014.html(last accessed 15 January 2018)."},{"key":"e_1_2_8_6_1","unstructured":"WHO.World Health Organization's guideline for the treatment of malaria Third edition. Geneva Switzerland: World Health Organization 2015."},{"key":"e_1_2_8_7_1","unstructured":"WHO.World Health Organization consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach Second edition. Geneva Switzerland: World Health Organization 2016."},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","author":"Riska P","year":"1999","journal-title":"Drug Metabol Dispos"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV\u20101 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P\u2010450","volume":"27","author":"Erickson DA","year":"1999","journal-title":"Drug Metabol Dispos"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00044.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00092-4"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039040-00002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040352"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)80079-4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.009019"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-008-9084-6"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.045765"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312811206040004"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01696.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0110-5"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32836533a5"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv207"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co\u2010medication","volume":"13","author":"St\u00f6hr W","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200107000-00004"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.054866"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200512000-00004"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200501000-00001"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00432.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282ef9695"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00689.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00066-2"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32833e0cb5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.77"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.336"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05265-11"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks207"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01153-15"},{"key":"e_1_2_8_38_1","unstructured":"WMA.World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects 2013[Online]. Available athttps:\/\/www.wma.net\/policies\u2010post\/wma\u2010declaration\u2010of\u2010helsinki\u2010ethical\u2010principles\u2010for\u2010medical\u2010research\u2010involving\u2010human\u2010subjects\/(accessed 5 April 2017)."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2015-0016"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv174"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks011"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9470-x"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00003"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00002"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13877"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13880"},{"key":"e_1_2_8_48_1","unstructured":"European Medicine Agency.Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products (EMA\/CHMP\/37646\/2009) 2012[Online]. Available atwww.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/02\/WC500121954.pdf(last accessed 18 May 2018)."},{"key":"e_1_2_8_49_1","unstructured":"Food and Drug Administration.Clinical pharmacogenomics: premarket evaluation in early\u2010phase clinical studies and recommendations for labeling[Online]. Silver Spring 2013. Available athttps:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM337169.pdf(last accessed 20 May 2018)."},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.11-0649"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0839-4"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/650732"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2006.01700.x"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02033.x"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-0277-7"},{"key":"e_1_2_8_56_1","unstructured":"WalimbwaSI LamordeM WaittC KaboggozaJP ElseL Byakika\u2010KinwikaP et al.Dolutegravir interactions with artemether\u2010lumefantrine and amodiaquine\u2010artesunate[Abstract #459]. Conference on Retroviruses and Opportunistic Infections (CROI 2018). Hynes Convention Centre Boston MA USA 4\u20137 March2018."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00292-13"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.190"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199910000-00006"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040209"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13821","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:39:32Z","timestamp":1775281172000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bcp.13821"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13821","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]}}}